2-Fluorophenylacetonitrile is an organic intermediate that can be obtained by reacting o-fluorobenzyl bromide and sodium cyanide. 2-Fluorophenylacetonitrile is a medium chemicalbook interbody of Prasugrel. Prasugrel is an oral antiplatelet drug jointly developed by Eli Lilly and its partner Daiichi Pharmaceuticals Sankyo and approved for marketing in the European Union on February 27, 2009.